Kazuhiro Kitajima1, Masaya Okada2, Toru Kashiwagi3, Kyoko Yoshihara2, Tazuko Tokugawa2, Akihiro Sawada2, Satoshi Yoshihara2, Yoshihiro Fujimori2, Koichiro Yamakado4. 1. Division of Nuclear Medicine and PET Center, Department of Radiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. kitajima@med.kobe-u.ac.jp. 2. Division of Hematology, Department of Internal Medicine Department of Transfusion Medicine and Cellular Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan. 3. Department of Healthcare office, Daimaru Matsuzaka Department Store, Osaka, 530-8202, Japan. 4. Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.
Abstract
PURPOSE: To determine the earliest optimal timing for assessment of early response following radioimmunotherapy in non-Hodgkin lymphoma patients using FDG-PET/CT. METHODS: FDG-PET/CT was performed prior to treatment (PET1), at 2 (PET2) weeks, and at 6 (PET3) weeks after 90Y-ibritumomab radioimmunotherapy in 55 patients. Response was evaluated based on the Deauville 5-point scale and Lugano criteria as well as semiquantitative analysis and compared with progression-free survival (PFS). RESULTS: PET 2 showed complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD) in 33, 13, 6, and 3 patients, respectively, while PET 3 in 41, 8, 3, and 3 patients, respectively. Mean SUVmax of 168 target lesions decreased over time (PET1, 2, 3; 5.58 ± 2.58, 1.87 ± 1.78, 1.75 ± 2.25, respectively). Progression or recurrence after a median of 12.6 months (range 2.6-72.0 months) was seen in 44 patients. Patients with CMR or metabolic response (CMR + PMR) on PET2 showed significantly longer PFS as compared to those who did not (p = 0.00028 and p = 0.029, respectively). A similar significant difference was observed based on PET3 (p = 0.00013 and p = 0.017, respectively). The same trend was observed when analyzing only the subgroup of patients with follicular lymphoma (N = 43/55) (p < 0.0001). CONCLUSION: Use of FDG-PET/CT findings with Lugano criteria for assessing early response to radioimmunotherapy after 6 weeks allowed for accurate evaluation and prognostic stratification, though scanning after 2 weeks was too soon to precisely evaluate response. KEY POINTS: • The optimal timing of FDG-PET/CT to obtain a suitable tool for assessment of response after 90 Y-ibritumomab radioimmunotherapy of lymphoma has not yet been defined. • Assessment after 6 weeks by FDG-PET/CT using the Lugano criteria accurately evaluates treatment response and prognosis. • FDG-PET/CT performed 2 weeks after radioimmunotherapy is too early as it significantly misses objective responses.
PURPOSE: To determine the earliest optimal timing for assessment of early response following radioimmunotherapy in non-Hodgkin lymphomapatients using FDG-PET/CT. METHODS: FDG-PET/CT was performed prior to treatment (PET1), at 2 (PET2) weeks, and at 6 (PET3) weeks after 90Y-ibritumomab radioimmunotherapy in 55 patients. Response was evaluated based on the Deauville 5-point scale and Lugano criteria as well as semiquantitative analysis and compared with progression-free survival (PFS). RESULTS: PET 2 showed complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD) in 33, 13, 6, and 3 patients, respectively, while PET 3 in 41, 8, 3, and 3 patients, respectively. Mean SUVmax of 168 target lesions decreased over time (PET1, 2, 3; 5.58 ± 2.58, 1.87 ± 1.78, 1.75 ± 2.25, respectively). Progression or recurrence after a median of 12.6 months (range 2.6-72.0 months) was seen in 44 patients. Patients with CMR or metabolic response (CMR + PMR) on PET2 showed significantly longer PFS as compared to those who did not (p = 0.00028 and p = 0.029, respectively). A similar significant difference was observed based on PET3 (p = 0.00013 and p = 0.017, respectively). The same trend was observed when analyzing only the subgroup of patients with follicular lymphoma (N = 43/55) (p < 0.0001). CONCLUSION: Use of FDG-PET/CT findings with Lugano criteria for assessing early response to radioimmunotherapy after 6 weeks allowed for accurate evaluation and prognostic stratification, though scanning after 2 weeks was too soon to precisely evaluate response. KEY POINTS: • The optimal timing of FDG-PET/CT to obtain a suitable tool for assessment of response after 90 Y-ibritumomab radioimmunotherapy of lymphoma has not yet been defined. • Assessment after 6 weeks by FDG-PET/CT using the Lugano criteria accurately evaluates treatment response and prognosis. • FDG-PET/CT performed 2 weeks after radioimmunotherapy is too early as it significantly misses objective responses.
Authors: A Grgic; U Nestle; K Scheidhauer; C Puskas; E Ballek; K Hohloch; J Schubert; J König; J Pinkert; L Truemper; D Hellwig; C-M Kirsch Journal: Nuklearmedizin Date: 2010-11-08 Impact factor: 1.379
Authors: Heather Jacene; John Crandall; Yvette L Kasamon; Richard F Ambinder; Steven Piantadosi; Donna Serena; Wayne Kasecamp; Richard L Wahl Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Henry N Wagner; Gregory A Wiseman; Carol S Marcus; Hani A Nabi; Conrad E Nagle; Darlene M Fink-Bennett; Dominick M Lamonica; Peter S Conti Journal: J Nucl Med Date: 2002-02 Impact factor: 10.057
Authors: Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Benoît Dupas; Franck Morschhauser; Thomas Gastinne; Steven Le Gouill; Loïc Campion; Jean-Luc Harousseau; William A Wegener; David M Goldenberg; Damien Huglo Journal: Haematologica Date: 2008-02-11 Impact factor: 9.941
Authors: Marijke De Saint-Hubert; Ellen Devos; Abdelilah Ibrahimi; Zeger Debyser; Luc Mortelmans; Felix M Mottaghy Journal: Am J Nucl Med Mol Imaging Date: 2012-07-10
Authors: Giovanni Storto; Amalia De Renzo; Teresa Pellegrino; Fabiana Perna; Teresa De Falco; Paola Erra; Anna Nardelli; Antonio Speranza; Michele Klain; Bruno Rotoli; Leonardo Pace Journal: Radiology Date: 2010-01 Impact factor: 11.105